| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.065 | 0.07 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.06 | 0.07 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.07 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.07 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.07 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.07 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.08 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.08 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |